

GUERNSEY STATUTORY INSTRUMENT

2021 No. 11

**The Medicines (Coronavirus and Influenza) (Bailiwick  
of Guernsey) (Amendment No. 2) Regulations, 2021**

<i>Made</i>	26 <sup>th</sup> January, 2021
<i>Coming into operation</i>	27 <sup>th</sup> January, 2021
<i>Laid before the States</i>	, 2021

THE COMMITTEE FOR HEALTH & SOCIAL CARE, in exercise of the powers conferred on it by sections 7(3) and (3A), 15, 34, 39, 75 and 132 of the Medicines (Human and Veterinary) (Bailiwick of Guernsey) Law, 2008<sup>a</sup>, section 15(2) and (3) of the Prescription Only Medicines (Human) (Bailiwick of Guernsey) Ordinance, 2009<sup>b</sup> (following consultation with the Policy & Resources Committee of the States of Guernsey, the Policy and Finance Committee of the States of Alderney and the Medical & Emergency Services Committee of the Chief Pleas) and all other powers enabling them in that behalf, hereby makes the following Regulations:-

---

<sup>a</sup> Order in Council No. V of 2009; amended by Ordinance No. XXIV of 2009; No. XLI of 2013; No. IX of 2016; and G.S.I. No. 39 of 2019.

<sup>b</sup> Ordinance No. XXV of 2009; amended by No. XXV of 2010; No. IX of 2016; No. XXXIV of 2020.

**Amendment of the 2020 Regulations.**

1. The Medicines (Coronavirus and Influenza) (Bailiwick of Guernsey) Regulations, 2020<sup>c</sup> ("**the principal Regulations**") are amended as set out in regulation 2.

2. For regulation 1(2) and (3) of the principal Regulations, substitute the following paragraphs –

"(2) Paragraph (1) refers to the following medicinal products–

- (a) COVID-19 mRNA Vaccine BNT162b2 concentrate for solution for injection, also known as the Pfizer-BioNTech COVID-19 Vaccine,
- (b) COVID-19 Vaccine AstraZeneca, solution for injection in multidose container COVID-19 Vaccine (ChAdOx1-S [recombinant]), also known as the COVID-19 Vaccine AstraZeneca, and
- (c) COVID-19 Vaccine Moderna dispersion for injection COVID-19 mRNA Vaccine (nucleoside modified), also known as the COVID-19 Vaccine Moderna.

---

<sup>c</sup> G.S.I. No. 125 of 2020; as amended by G.S.I. No. 3 of 2021.

(3) The designation of each of those medicinal products under paragraph (1) is subject to any conditions specified by the UK licensing authority for the authorisation of the respective medicinal product on a temporary basis under regulation 174 of the Human Medicines Regulations 2012<sup>d</sup>, which may include conditions specified under regulation 174A of those Regulations.

(4) In paragraph (3), “the UK licensing authority” means the licensing authority within the meaning given by regulation 6(2) of the Human Medicines Regulations 2012.”.

3. Revoke Schedules 1 and 2 to the principal Regulations.

**Citation.**

4. These Regulations may be cited as the Medicines (Coronavirus and Influenza) (Amendment No. 2) (Bailiwick of Guernsey) Regulations, 2021.

**Commencement**

5. These Regulations shall come into force on the 27<sup>th</sup> January, 2021.

---

<sup>d</sup> UK S.I. 2012 No. 1916.

Dated this 26<sup>th</sup> day of January, 2021



Deputy A.H. Brouard  
President of the Committee for Health & Social Care  
For and on behalf of the Committee

---

EXPLANATORY NOTE

*(This note is not part of the Regulations)*

These Regulations amend the Medicines (Coronavirus and Influenza) (Bailiwick of Guernsey) Regulations, 2020 ("**the principal Regulations**").

Regulation 2 substitutes regulation 1 of the principal Regulations to add the COVID-19 Vaccine Moderna to the two other vaccines (the Pfizer-BioNTech COVID-19 Vaccine and the COVID-19 Vaccine AstraZeneca) already designated to be used for vaccination or immunisation against the coronavirus. The designation of each vaccine is subject to the conditions of the temporary authorisation given to each of those vaccines under regulation 174 of the Human Medicines Regulations 2012 (UK).

Regulation 3 revokes Schedules 1 and 2 to the principal Regulations, which set out the conditions of the temporary authorisation given to the Pfizer-BioNTech COVID-19 Vaccine and the COVID-19 Vaccine AstraZeneca respectively. The applicable

conditions for each vaccine are those published by the UK Government and in force at any given time.

These Regulations will come into force on the 27<sup>th</sup> January, 2021.

